Androgen Deprivation Therapy (ADT)
 

What is ADT?

What is done? What can I expect? What are the possible side-effects and risks?
  • Androgens are hormones that promote male characteristics such as facial hair, sexual function and muscle mass. Testosterone is the main androgen.
  • Prostate cancer cells need androgens to grow.
  • Androgen deprivation therapy (ADT), a type of treatment for prostate cancer, blocks the production or effects of testosterone and other male hormones.
  • ADT is most often used to treat:
    • Cancer that has spread outside the prostate
    • Recurrence of prostate cancer after another therapy has been used
    • Men who are at high risk of experiencing cancer recurrence after surgery or radiation therapy
  • “Hormone therapy” is another name for ADT. Although these terms can be used interchangeably, Prostate Cancer Canada uses ADT (it is more specific to prostate cancer treatment).
  • This therapy affects the whole body rather than a particular area

Watch Dr. Shabbir's Alibhai's Expert Angle Video on Hormone Therapy

For more information and support:


Plaid for Dad


Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Honouring dad this Father’s Day the Canadian way: In plaid

TORONTO, ON – (May 8, 2018) – Plaid replaces business-casual on Friday, June 15 as hundreds of thousands of Canadians don the iconic Canadian attire all to honour dad and end prostate cancer.
More

The Finger – A tried and true method to save lives

TORONTO, CANADA (May 8, 2018) – Every day, more and more methods to detect prostate cancer are being explored, but the tried and true methods of a digital rectal examination (DRE) – where a healthcare professional inserts a gloved finger into the rectum to check for abnormalities, paired with a blood test known as the prostate-specific antigen (PSA) test – which you can get through your family doctor, are still the long-standing proven ways to save a life.
More

Landmark study links tumour evolution to prostate cancer severity

Toronto (April 19, 2018) – Findings from Canadian Prostate Cancer Genome Network (CPC-GENE) researchers and their collaborators, published today in Cell, show that the aggressiveness of an individual prostate cancer can be accurately assessed by looking at how that tumour has evolved.
More


Click here for news archive